Repligen(RGEN)

Search documents
Repligen(RGEN) - 2023 Q3 - Earnings Call Transcript
2023-10-31 17:16
Repligen Corporation (NASDAQ:RGEN) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Sondra Newman – Head of Investor Relations Tony Hunt – Chief Executive Officer Jason Garland – Chief Financial Officer Conference Call Participants Jacob Johnson – Stephens Conor McNamara – RBC Capital Markets Dan Arias – Stifel Puneet Souda – Leerink Partners Matt Larew – William Blair Matt Hewitt – Craig-Hallum Capital Group Tim Daley – Wells Fargo Rachel Vatnsdal – J.P. Morgan Dan Leonard ...
Repligen(RGEN) - 2023 Q2 - Quarterly Report
2023-08-02 20:20
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to___________ Commission File Number 000-14656 REPLIGEN CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 04-2729386 (State or Other Jur ...
Repligen(RGEN) - 2023 Q2 - Earnings Call Transcript
2023-08-02 19:26
Repligen Corporation (NASDAQ:RGEN) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Jacob Johnson - Stephens Dan Arias - Stifel Matt Larew - William Blair Rachel Vatnsdal - J.P. Morgan Paul Knight - KeyBanc Capital Markets Conor McNamara - RBC Capital Markets Matt Hewitt - Craig H ...
Repligen(RGEN) - 2023 Q1 - Quarterly Report
2023-05-02 20:42
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to___________ Commission File Number 000-14656 REPLIGEN CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 04-2729386 (State or Other Ju ...
Repligen(RGEN) - 2023 Q1 - Earnings Call Transcript
2023-05-02 17:51
Repligen Corporation (NASDAQ:RGEN) Q1 2023 Earnings Conference Call May 2, 2023 8:30 AM ET Company Participants Sondra Newman - Head, IR Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Jacob Johnson - Stephens Puneet Souda - SVB Securities Julia Kim - JPM Chase Matt Larew - William Blair Paul Knight - KeyBanc Capital Markets Lisa Garcia - UBS Matt Hewitt - Craig-Hallum Brandon Couillard - Jefferies Operator Good day, la ...
Repligen(RGEN) - 2022 Q4 - Annual Report
2023-02-22 21:47
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 04-2729386 (State or other jurisdiction of incorporat ...
Repligen(RGEN) - 2022 Q4 - Earnings Call Transcript
2023-02-22 19:38
Start Time: 08:30 January 1, 0000 9:37 AM ET Repligen Corporation (NASDAQ:RGEN) Q4 2022 Earnings Conference Call February 22, 2023, 08:30 AM ET Company Participants Tony Hunt - President and CEO Jon Snodgres - CFO Sondra Newman - Head, IR Conference Call Participants Jacob Johnson - Stephens Dan Arias - Stifel Puneet Souda - SVB Securities Elizabeth Garcia - UBS Matt Larew - William Blair Brandon Couillard - Jefferies Matt Hewitt - Craig-Hallum Conor McNamara - RBC Capital Markets Operator Good day, ladies ...
Repligen(RGEN) - 2022 Q3 - Quarterly Report
2022-11-01 20:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 REPLIGEN CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 04-2729386 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 41 Seyon Street, Bldg. 1, Suite 100 Waltham, MA 02453 (Address of Principal Executive Offices) (Zip Code) For the quarterly period ended September ...
Repligen(RGEN) - 2022 Q3 - Earnings Call Transcript
2022-11-01 17:17
Repligen Corporation (NASDAQ:RGEN) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Sondra Newman – Head-Investor Relations Tony Hunt – President and Chief Executive Officer Jon Snodgres – Chief Financial Officer Conference Call Participants Puneet Souda – SVB Securities Dan Arias – Stifel Julia Qin – JPMorgan Jacob Johnson – Stephens Paul Knight – KeyBanc Madeline Mollman – William Blair Liza Garcia – UBS Matt Hewitt – Craig-Hallum Capital Group Brandon Couillard – Jefferie ...
Repligen(RGEN) - 2022 Q2 - Quarterly Report
2022-08-02 20:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to___________ Commission File Number 000-14656 REPLIGEN CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 04-2729386 (State or Other Jur ...